Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.
Aerts JGJV, de Goeje PL, Cornelissen R, Kaijen-Lambers MEH, Bezemer K, van der Leest CH, Mahaweni NM, Kunert A, Eskens FALM, Waasdorp C, Braakman E, van der Holt B, Vulto AG, Hendriks RW, Hegmans JPJJ, Hoogsteden HC. Aerts JGJV, et al. Among authors: eskens falm. Clin Cancer Res. 2018 Feb 15;24(4):766-776. doi: 10.1158/1078-0432.CCR-17-2522. Epub 2017 Dec 12. Clin Cancer Res. 2018. PMID: 29233904 Clinical Trial.
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
van Zuylen L, Bridgewater J, Sparreboom A, Eskens FA, de Bruijn P, Sklenar I, Planting AS, Choi L, Bootle D, Mueller C, Ledermann JA, Verweij J. van Zuylen L, et al. Clin Cancer Res. 2004 Mar 15;10(6):1949-55. doi: 10.1158/1078-0432.ccr-02-0995. Clin Cancer Res. 2004. PMID: 15041711 Free article. Clinical Trial.
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jonge MJ, Thomas J, Eskens FA, van Schaik RH, Selleslach J, Ter Steeg J, Lefebvre P, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. Soepenberg O, et al. Clin Cancer Res. 2005 Feb 15;11(4):1504-11. doi: 10.1158/1078-0432.CCR-04-1758. Clin Cancer Res. 2005. PMID: 15746053 Free article. Clinical Trial.
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Hoekstra R, Dumez H, Eskens FA, van der Gaast A, Planting AS, de Heus G, Sizer KC, Ravera C, Vaidyanathan S, Bucana C, Fidler IJ, van Oosterom AT, Verweij J. Hoekstra R, et al. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6908-15. doi: 10.1158/1078-0432.CCR-05-0720. Clin Cancer Res. 2005. PMID: 16203782 Clinical Trial.
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Eskens FA, de Jonge MJ, Bhargava P, Isoe T, Cotreau MM, Esteves B, Hayashi K, Burger H, Thomeer M, van Doorn L, Verweij J. Eskens FA, et al. Clin Cancer Res. 2011 Nov 15;17(22):7156-63. doi: 10.1158/1078-0432.CCR-11-0411. Epub 2011 Oct 5. Clin Cancer Res. 2011. PMID: 21976547 Clinical Trial.
Evaluation of patient enrollment in oncology phase I clinical trials.
van der Biessen DA, Cranendonk MA, Schiavon G, van der Holt B, Wiemer EA, Eskens FA, Verweij J, de Jonge MJ, Mathijssen RH. van der Biessen DA, et al. Oncologist. 2013;18(3):323-9. doi: 10.1634/theoncologist.2012-0334. Epub 2013 Feb 21. Oncologist. 2013. PMID: 23429738 Free PMC article.
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.
de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, Eskens FA, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH. de Graan AJ, et al. Clin Cancer Res. 2013 Jun 15;19(12):3316-24. doi: 10.1158/1078-0432.CCR-12-3786. Epub 2013 May 2. Clin Cancer Res. 2013. PMID: 23640974 Free PMC article.
138 results